RNAi play Sirnaomics raises $10M

Sirnaomics Inc. (Gaithersburg, Md.) raised $10 million in a series B round from Hong Kong-based venture firm Value Measured Investment Ltd. CMO Michael Molyneaux told BioCentury the round will allow Sirnaomics to complete Phase I and Phase II studies in the U.S. of STP705 to treat hypertrophic scars.

STP705 is a histidine-lysine polymer (HKP) nanoparticle encapsulation of two siRNAs targeting two proteins involved in scar formation: transforming growth factor (TGF) beta 1 ( TGFB1) and cyclooxygenase-2 ( COX-2). ...